Oramed Pharmaceuticals Inc.
$3.83
▲
0.88%
2026-04-21 08:41:00
www.oramed.com
NCM: ORMP
Explore Oramed Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$151.27 M
Current Price
$3.83
52W High / Low
$3.96 / $1.98
Stock P/E
3.45
Book Value
$4.98
Dividend Yield
0%
ROCE
-7.12%
ROE
37.1%
Face Value
—
EPS
$1.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.25
Debt / Equity
0.41
Current Ratio
6.98
Quick Ratio
6.98
Forward P/E
-44.12
Price / Sales
71.39
Enterprise Value
$17.71 M
EV / EBITDA
-1.18
EV / Revenue
8.85
Rating
None
Target Price
$6.25
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
- Meaningful dividend yield is available.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
| 2. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 3. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 4. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 5. | MBX Biosciences, Inc. | $33.78 | — | $1.6 B | — | -26.53% | -27.76% | $44.89 / $7.09 | $8.22 |
| 6. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 7. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 2 M | 0 M | — |
| Operating Profit | -5.67 M | -2.43 M | -2.49 M | -4.5 M | -3.6 M | — |
| Net Profit | 10.01 M | 48.4 M | 13.29 M | -7.64 M | -10.19 M | — |
| EPS in Rs | 0.25 | 1.2 | 0.33 | -0.19 | -0.25 | -0.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2 M | 0 M | 1.34 M | 2.7 M |
| Operating Profit | -15.09 M | -12.78 M | -15.77 M | -40.6 M |
| Net Profit | 64.05 M | -19.06 M | 5.53 M | -36.56 M |
| EPS in Rs | 1.58 | -0.47 | 0.14 | -0.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 230.86 M | 155.28 M | 220.55 M | 161.64 M |
| Total Liabilities | 31.12 M | 9.93 M | 57.66 M | 10.49 M |
| Equity | 199.74 M | 146.26 M | 163.82 M | 151.81 M |
| Current Assets | 133.27 M | 143.22 M | 162.58 M | 157.11 M |
| Current Liabilities | 19.09 M | 5.68 M | 53.21 M | 5.75 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.14 M | -8.41 M | -10.29 M | -27.92 M |
| Investing CF | 5.44 M | 105.82 M | -73.04 M | 30.21 M |
| Financing CF | -4.74 M | -52.04 M | 51.98 M | 10.78 M |
| Free CF | -11.08 M | -8.43 M | -10.55 M | -28.41 M |
| Capex | -1.93 M | -0.02 M | -0.25 M | -0.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | -50.43% | — |
| Earnings Growth % | 436.04% | -444.98% | 115.11% | — |
| Profit Margin % | 3202.5% | — | 412.31% | -1352.61% |
| Operating Margin % | -754.4% | — | -1176.79% | -1501.96% |
| Gross Margin % | 0.65% | — | — | — |
| EBITDA Margin % | 3772.25% | — | 546.34% | -1391.27% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-01-16 | $0.25 |
Stock Splits
No stock split history available.